Oxford Immunotec Global PLC (NASDAQ:OXFD) Cut to “Sell” at Zacks Investment Research

Oxford Immunotec Global PLC (NASDAQ:OXFD) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Saturday, November 4th.

According to Zacks, “Oxford Immunotec Global PLC is a medical diagnostics company. It develops new tests for various diseases based on its, patented T cell measurement technology. The company’s first product is the T-SPOT(R). Oxford Immunotec Global PLC is headquartered in Abingdon, the United Kingdom. “

A number of other analysts also recently issued reports on OXFD. Cowen and Company restated a “buy” rating and issued a $19.00 price target on shares of Oxford Immunotec Global PLC in a research report on Thursday, September 28th. Piper Jaffray Companies restated a “buy” rating and issued a $26.00 price target on shares of Oxford Immunotec Global PLC in a research report on Thursday, August 3rd. Robert W. Baird reiterated a “buy” rating and set a $20.00 target price on shares of Oxford Immunotec Global PLC in a research report on Wednesday, November 1st. BTIG Research assumed coverage on Oxford Immunotec Global PLC in a research report on Thursday, September 28th. They set a “buy” rating and a $21.00 target price for the company. Finally, ValuEngine downgraded Oxford Immunotec Global PLC from a “hold” rating to a “sell” rating in a report on Tuesday, October 31st. Three research analysts have rated the stock with a sell rating and four have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $19.75.

Shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) opened at $13.11 on Friday. The company has a debt-to-equity ratio of 0.38, a current ratio of 4.72 and a quick ratio of 4.30. Oxford Immunotec Global PLC has a fifty-two week low of $12.19 and a fifty-two week high of $19.51.

ILLEGAL ACTIVITY NOTICE: “Oxford Immunotec Global PLC (NASDAQ:OXFD) Cut to “Sell” at Zacks Investment Research” was originally reported by Week Herald and is owned by of Week Herald. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://weekherald.com/2017/11/15/oxford-immunotec-global-plc-oxfd-stock-rating-lowered-by-zacks-investment-research.html.

In related news, Director Richard A. Sandberg sold 3,000 shares of Oxford Immunotec Global PLC stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $13.35, for a total transaction of $40,050.00. Following the completion of the sale, the director now owns 17,778 shares of the company’s stock, valued at $237,336.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Peter Wrighton-Smith sold 55,000 shares of Oxford Immunotec Global PLC stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $16.78, for a total value of $922,900.00. The disclosure for this sale can be found here. Insiders have sold 61,000 shares of company stock worth $1,010,410 in the last 90 days. Insiders own 8.11% of the company’s stock.

A number of large investors have recently made changes to their positions in the business. Redmile Group LLC lifted its holdings in Oxford Immunotec Global PLC by 7.5% in the second quarter. Redmile Group LLC now owns 2,155,949 shares of the company’s stock valued at $36,263,000 after acquiring an additional 151,100 shares during the period. Alyeska Investment Group L.P. lifted its holdings in Oxford Immunotec Global PLC by 44.0% in the third quarter. Alyeska Investment Group L.P. now owns 1,355,529 shares of the company’s stock valued at $22,773,000 after acquiring an additional 413,904 shares during the period. RTW Investments LP lifted its holdings in Oxford Immunotec Global PLC by 21.9% in the third quarter. RTW Investments LP now owns 1,032,370 shares of the company’s stock valued at $17,344,000 after acquiring an additional 185,453 shares during the period. Wasatch Advisors Inc. lifted its holdings in Oxford Immunotec Global PLC by 35.5% in the third quarter. Wasatch Advisors Inc. now owns 574,174 shares of the company’s stock valued at $9,646,000 after acquiring an additional 150,343 shares during the period. Finally, Cortina Asset Management LLC raised its stake in shares of Oxford Immunotec Global PLC by 12.8% during the 3rd quarter. Cortina Asset Management LLC now owns 563,290 shares of the company’s stock worth $9,463,000 after buying an additional 63,765 shares during the period. 78.79% of the stock is owned by institutional investors.

About Oxford Immunotec Global PLC

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Get a free copy of the Zacks research report on Oxford Immunotec Global PLC (OXFD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply